PriceTargets.com logo

Damora Therapeutics, Inc. Common Stock - DMRA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $43.67
  • Forecasted Upside: 127.67%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 2 Strong Buy Ratings
$19.18 As of 03/19/2026 04:02 PM ET
▼ -1.97 (-9.31%)

This chart shows the closing price for DMRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Damora Therapeutics, Inc. Common Stock Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DMRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DMRA

Analyst Price Target is $43.67
▲ +127.67% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Damora Therapeutics, Inc. Common Stock in the last 3 months. The average price target is $43.67, with a high forecast of $46.00 and a low forecast of $40.00. The average price target represents a 127.67% upside from the last price of $19.18.

This chart shows the closing price for DMRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 investment analysts is to moderate buy stock in Damora Therapeutics, Inc. Common Stock. This rating has held steady since December 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 2 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/17/2026
  • 2 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026

Latest Recommendations

  • 2 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/17/2026GuggenheimReiterated RatingBuy ➝ Buy$36.00 ➝ $40.00
2/17/2026UBS GroupInitiated CoverageBuy$45.00
2/2/2026Lifesci CapitalUpgradeStrong-Buy
1/9/2026Zacks ResearchUpgradeHold
1/7/2026Leerink PartnersUpgradeStrong-Buy
1/7/2026Leerink PartnersInitiated CoverageOutperform$46.00
12/29/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/8/2025GuggenheimBoost TargetBuy ➝ Buy$32.00 ➝ $36.00
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/1/2025GuggenheimInitiated CoverageBuy$32.00
12/1/2025GuggenheimInitiated CoverageBuy$32.00
11/24/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/17/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/5/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/14/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/17/2024OppenheimerBoost TargetOutperform ➝ Outperform$9.00 ➝ $10.00
6/10/2024OppenheimerLower TargetOutperform ➝ Outperform$250.00 ➝ $225.00
9/28/2023HC WainwrightDowngradeBuy ➝ Neutral
8/21/2023HC WainwrightLower TargetBuy ➝ Buy$300.00 ➝ $50.00
8/15/2023Leerink PartnersDowngradeOutperform ➝ Market Perform
8/15/2023SVB SecuritiesDowngradeOutperform ➝ Market Perform
8/15/2023Leerink PartnersReiterated RatingOutperform ➝ Market Perform$325.00 ➝ $50.00
8/1/2023HC WainwrightReiterated RatingBuy ➝ Buy$300.00
8/1/2023OppenheimerReiterated RatingOutperform ➝ Outperform$300.00
6/20/2023OppenheimerInitiated CoverageOutperform
5/15/2023HC WainwrightReiterated RatingBuy
3/17/2023Cantor FitzgeraldInitiated CoverageOverweight$400.00
3/10/2023Credit Suisse GroupReiterated RatingOutperform$150.00
8/3/2022Leerink PartnersLower TargetOutperform$400.00 ➝ $325.00
8/6/2021Credit Suisse GroupLower TargetOutperform$300.00 ➝ $175.00
(Data available from 3/19/2021 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2025
  • 0 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2025
  • 1 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Damora Therapeutics, Inc. Common Stock logo
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Read More

Today's Range

Now: $19.18
Low: $18.50
High: $22.04

50 Day Range

MA: $27.00
Low: $20.37
High: $32.30

52 Week Range

Now: $19.18
Low: $2.01
High: $38.33

Volume

240,150 shs

Average Volume

218,704 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Damora Therapeutics, Inc. Common Stock?

The following sell-side analysts have issued reports on Damora Therapeutics, Inc. Common Stock in the last twelve months: Guggenheim, Leerink Partners, Lifesci Capital, UBS Group AG, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for DMRA.

What is the current price target for Damora Therapeutics, Inc. Common Stock?

0 Wall Street analysts have set twelve-month price targets for Damora Therapeutics, Inc. Common Stock in the last year. Their average twelve-month price target is $43.67, suggesting a possible upside of 127.7%. Leerink Partners has the highest price target set, predicting DMRA will reach $46.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $40.00 for Damora Therapeutics, Inc. Common Stock in the next year.
View the latest price targets for DMRA.

What is the current consensus analyst rating for Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock currently has 1 sell rating, 1 hold rating, 2 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DMRA.

What other companies compete with Damora Therapeutics, Inc. Common Stock?

Other companies that are similar to Damora Therapeutics, Inc. Common Stock include Trilogy Metals, Arcturus Therapeutics, ALT5 Sigma, Molecular Partners and Eledon Pharmaceuticals. Learn More about companies similar to Damora Therapeutics, Inc. Common Stock.

How do I contact Damora Therapeutics, Inc. Common Stock's investor relations team?

Damora Therapeutics, Inc. Common Stock's physical mailing address is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. The company's listed phone number is 45-7070-5210 and its investor relations email address is [email protected]. The official website for Damora Therapeutics, Inc. Common Stock is galecto.com. Learn More about contacing Damora Therapeutics, Inc. Common Stock investor relations.